Summary
The claim (FDA first approval year) is not addressed in the provided prescribing information excerpts, so it cannot be verified against the label.
Category Scores
Accurate Statements
Unsupported Statements
Lantus (insulin glargine) was first approved by the U.S. Food and Drug Administration (FDA) in 2000.
The provided label excerpts do not include information about FDA approval date/year.
Contradictions
Important Omissions
FDA approval year/date information is not present in the provided prescribing information excerpts needed to verify the claim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim concerns historical approval timing and does not introduce dosing, contraindication, or safety instructions that could directly affect patient management based on the provided label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Claim not supported by the provided FDA-approved prescribing information excerpts.
Suggested Improvement
Limit statements to label-supported content (e.g., indications, dosage/admin instructions, contraindications, warnings/precautions, and described product formulation details) or provide label text that includes approval timing.